SRINAGAR: Novo Nordisk India Pvt. Ltd. and Sher-i-Kashmir Institute of Medical Sciences (SKIMS), Soura have signed a landmark Memorandum of Understanding (MoU) to embark on a strategic collaboration focused on advancing clinical trials in India. This partnership marks a significant milestone for both organisations as they join forces to innovate and transform the clinical research landscape, ultimately aiming to improve patient outcomes. Key dignitaries including Dr Mohammed Ashraf Ganie (Director, SKIMS); Dr Shariq Massodi – Dean, Medical Faculty, SKIMS and Dr Muzaffer Wani - Professor of Nephrology, SKIMS emphasised the collaborative potential of this initiative.
Commenting on the MoU signing, Vikrant Shrotriya, Managing Director and Corporate Vice President, Novo Nordisk India Pvt. Ltd., said, “This partnership underscores our unwavering commitment to redefining the future of clinical research in India. By uniting our global expertise in innovative therapeutics with SKIMS’ exceptional medical infrastructure, we aim to create transformative healthcare solutions. This partnership aspires to bridge gaps in access to advanced medicines, delivering life-changing outcomes for patients in underserved communities and beyond.”
Dr. Mohammed Ashraf Ganie - Director-SKIMS said, “This collaboration represents a significant step towards elevating clinical research standards in the region. By collaborating with Novo Nordisk India Pvt. Ltd., SKIMS aims to contribute to groundbreaking advancements in medical science while ensuring that the people of Jammu and Kashmir have access to world-class healthcare. Together, we are committed to transforming patient care and addressing the unmet medical needs of our community.”
A first of its kind, this MoU for clinical trials with a medical institute in the region, is valid for three years and opens doors to long-term collaboration. The partnership aims to explore groundbreaking solutions in cardiology, obesity, nephrology and rare diseases by leveraging Novo Nordisk’s expertise in developing advanced therapeutics and SKIMS’ robust medical infrastructure. As part of the MoU, Novo Nordisk will contribute to building research capacity by providing resources, clinical research, relevant trainings and project-related equipment. This initiative also aims to enhance the capabilities of the clinical research team at SKIMS, ensuring the outreach of life-saving medicines to larger patient population. Meanwhile, SKIMS will play a pivotal role in expediting the approval process for clinical trials, facilitating patient participation, care and ensuring their safety and convenience.
This collaboration between Novo Nordisk India and SKIMS sets a benchmark for clinical research in the region, reflecting a shared vision to drive innovation and improve healthcare accessibility. By combining global expertise with local insights, this partnership is poised to deliver transformative outcomes for patients, particularly in Jammu and Kashmir. Together, the two organizations aim to pave the way for groundbreaking therapeutic interventions, ensuring that world-class treatments reach those who need them most and setting a strong foundation for future advancements in Indian healthcare.
About Sher-i-Kashmir Institute of Medical Sciences (SKIMS)
Sher-i-Kashmir Institute of Medical Sciences is a Post Graduate Institute for training, research and patient care. With this objective, various committees appointed by the Government of Jammu and Kashmir identified the specialties in which postgraduate and post doctoral courses would be undertaken. By an Act of Legislature on 19th August 1983, Sher-i-Kashmir Institute of Medical Sciences was granted a Deemed University status.For more information, visit our website- www.skims.ac.in
About Novo Nordisk India Pvt. Ltd.
Novo Nordisk India was established in 1994 with its headquarters in Bengaluru, Karnataka. The company serves as the India affiliate of Novo Nordisk A/S- a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk A/S employs over 69,000 people in 80 countries and markets its products in around 170 countries.
